A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

Inclusion Criteria

• Participants must be females of post-menopausal status with HR+, HER2- breast cancer that has spread to internal organs
• Participants must have had at least one endocrine therapy
• Participants must be willing to use a device to answer daily questions about how they are doing for the duration of their participation in the study
• If participant has diarrhea from a previous treatment, they should talk to their doctor to ensure they have recovered enough to participate in this study

Exclusion Criteria

• Participants must not have breast cancer that has spread to the brain if untreated and with symptoms
• Participants must not have had any systemic treatment after their breast cancer has spread unless it is endocrine therapy
• Participants must not have certain active infections including HIV or hepatitis
• Participants must not be pregnant or breastfeeding
• Participants must not have certain types of cancers or certain previous cancer treatments
• Participants must not have certain serious medical conditions, including heart or lung disease, or have had certain types of tissue or organ transplants